ShockWave Medical, Inc. (SWAV)
| Market Cap | 6.77B |
| Revenue (ttm) | 429.89M |
| Net Income (ttm) | 88.03M |
| Shares Out | 36.14M |
| EPS (ttm) | 2.36 |
| PE Ratio | 79.37 |
| Forward PE | 61.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,750 |
| Open | 187.23 |
| Previous Close | 189.49 |
| Day's Range | 185.06 - 190.66 |
| 52-Week Range | 113.36 - 320.54 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 264.69 (+41.3%) |
| Earnings Date | Feb 16, 2023 |
About SWAV
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists thro... [Read more]
Financial Performance
In 2021, SWAV's revenue was $237.15 million, an increase of 249.83% compared to the previous year's $67.79 million. Losses were -$9.14 million, -86.09% less than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is $264.69, which is an increase of 41.30% from the latest price.
News
Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status
Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended Guidance Expands Number of Hospitals that Can Access IVL to I...
3 Pharma Stocks That Will Mint Millionaires
In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB) climbed 6% so far this year.
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues
ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.
Can Shockwave Medical (SWAV) Keep the Earnings Surprise Streak Alive?
Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shockwave Medical to Acquire Neovasc
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for t...
Shockwave Medical Announces Agreement to Acquire Neovasc
Neovasc's Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market
Is the Options Market Predicting a Spike in ShockWave Medical (SWAV) Stock?
Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.
Shockwave Medical Provides Quarterly Earnings Release Dates for 2023
SANTA CLARA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex ca...
The 7 Best Retirement Stocks for Investors Over 50
The best retirement stocks for investors over 50 have reliability in common. Retirement stocks come in a few flavors, but the best retirement stocks for investors over 50 provide a mix of growth, stab...
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left
we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.
After Plunging 10.9% in 4 Weeks, Here's Why the Trend Might Reverse for Shockwave Medical (SWAV)
Shockwave Medical (SWAV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...
Why Is Shockwave Medical (SWAV) Down 8.3% Since Last Earnings Report?
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock?
3 Medical Instruments Stocks With Potential to Outperform
Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.
3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects
The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most.
Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference
SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascula...
Shockwave Medical Publishes Inaugural ESG Report
SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascula...
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 35.29% and 4.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical Reports Third Quarter 2022 Financial Results
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex ca...
What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?
Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.
Two stocks that are ‘immune' to what the Fed does
Fed Chair Jerome Powell made it somewhat clear this week that “pausing” was not an option just yet. (read more) That paints a not-so-healthy picture for stocks moving forward.
Three stocks that allow investors forget about the Fed, according to strategist Peter Andersen
Peter Andersen, chief investment officer at Andersen Capital Management, joins 'Power Lunch' to discuss Fed guidance, stocks that show interest rate resilience, and investments in innovative technolog...